Oncolytics targets accelerated approval for oncolytic virus therapy

The company intends to start a registrational Phase II trial of pelareorep and chemotherapy combination for breast cancer in 2025.

Oct 8, 2024 - 04:00

Oncolytics targets accelerated approval for oncolytic virus therapy

The company intends to start a registrational Phase II trial of pelareorep and chemotherapy combination for breast cancer in 2025.

Read the original article

Tags:

Previous Article

EMA starts review into hair loss drugs about potential link to suicidal thoughts

Activist investor Starboard forges $1bn stake in Pfizer to swing profits

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

AstraZeneca to withdraw Covid-19 vaccine globally

AstraZeneca to withdraw Covid-19 vaccine globally

May 9, 2024

Reality Bites: Disappointment in the R&D Sector

Reality Bites: Disappointment in the R&D Sector

Apr 16, 2023

Novo Nordisk stops trial of Ozempic in kidneys as interim analysis shows success

Novo Nordisk stops trial of Ozempic in kidneys as inter...

Oct 17, 2023